Clinical Trial Update: Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006/KEYNOTE-006) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing two pembrolizumab dosing schedules with ipilimumab in advanced melanoma completed; results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• ipilimumab (ipilimumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Melanoma | Phase 3 | Status: COMPLETED | Results posted: 2016-01-14